[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654490":3},{"organization":4,"outcomesModule":7,"designInfo":52,"detailedDescription":63,"studyPopulation":11,"armGroups":64,"interventions":77,"overallOfficials":11,"centralContacts":87,"locations":95,"responsibleParty":211,"collaborators":11,"id":215,"slug":216,"hasResults":217,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":11,"eligibilityCriteria":221,"healthyVolunteers":217,"sex":222,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":11,"studyType":228,"phases":229,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":110,"whyStopped":11,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},{"fullName":5,"class":6},"Capital Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":39},[9],{"measure":10,"description":11,"timeFrame":12},"Cerebral Infarct Volume on Day 8",null,"Day 8",[14,17,20,24,28,31,33,36],{"measure":15,"description":11,"timeFrame":16},"NIHSS Score at 24 Hours","24 hours",{"measure":18,"description":19,"timeFrame":12},"NIHSS Score on Day 8","The NIHSS ranges from 0 to 42, with higher scores indicating greater neurological impairment and a worse outcome.",{"measure":21,"description":22,"timeFrame":23},"Change in NIHSS Score From Baseline to Day 8","The NIHSS ranges from 0 to 42. Change is calculated as the Day 8 score minus the baseline score.","Baseline to Day 8",{"measure":25,"description":26,"timeFrame":27},"mRS Score of 0-1 at 90 Days","The mRS ranges from 0 to 6, with higher scores indicating greater disability or death.","90 Days",{"measure":29,"description":30,"timeFrame":27},"mRS Score of 0-2 at 90 Days","The mRS ranges from 0 to 6, with higher scores indicating greater disability or death",{"measure":32,"description":26,"timeFrame":27},"Distribution of mRS scores at 90 Days",{"measure":34,"description":35,"timeFrame":27},"EQ-5D-5L at 90 Days","The EQ-5D-5L index score ranges from -0.391 to 1.000 using the Chinese value set, with higher scores indicating better health-related quality of life.",{"measure":37,"description":38,"timeFrame":27},"Barthel Index Score of 95-100 at 90 Days","The Barthel Index ranges from 0 to 100, with higher scores indicating greater independence in activities of daily living.",[40,44,47,50],{"measure":41,"description":42,"timeFrame":43},"Neurological Deterioration Within 24 Hours","an increase of ≥4 points in the NIHSS score from baseline","Within 24 hours",{"measure":45,"description":11,"timeFrame":46},"Symptomatic Intracranial Hemorrhage Within 8 Days","Within 8 Days",{"measure":48,"description":11,"timeFrame":49},"All Cause Mortality at 90 Days","Within 90 days",{"measure":51,"description":11,"timeFrame":46},"Intracranial Hemorrhage Within 8 Days",{"allocation":53,"interventionModel":54,"interventionModelDescription":11,"primaryPurpose":55,"observationalModel":11,"timePerspective":11,"maskingInfo":56},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":57,"maskingDescription":11,"whoMasked":58},"QUADRUPLE",[59,60,61,62],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Eligible participants will be randomly assigned to receive anisodine hydrobromide or matching placebo in addition to standard care, with efficacy and safety assessed during follow-up.",[65,71],{"label":66,"type":67,"description":68,"interventionNames":69},"Anisodine Hydrobromide Group","EXPERIMENTAL","Participants will receive anisodine hydrobromide combined with endovascular thrombectomy.",[70],"Drug: Anisodine Hydrobromide",{"label":72,"type":73,"description":74,"interventionNames":75},"Anisodine Hydrobromide placebo","PLACEBO_COMPARATOR","Participants will receive placebo combined with endovascular thrombectomy.",[76],"Drug: Anisodine Hydrobromide Placebo",[78,83],{"type":79,"name":80,"description":81,"armGroupLabels":82,"otherNames":11},"DRUG","Anisodine Hydrobromide","Anisodine hydrobromide, 2 mg per dose, diluted in 0.9% sodium chloride solution and administered by intravenous infusion twice daily for a total of 14 doses.",[66],{"type":79,"name":84,"description":85,"armGroupLabels":86,"otherNames":11},"Anisodine Hydrobromide Placebo","An equivalent volume of 0.9% sodium chloride solution, administered by intravenous infusion twice daily for a total of 14 doses.",[72],[88,93],{"name":89,"role":90,"phone":91,"phoneExt":11,"email":92},"Xunming Ji, PhD\u002FMD","CONTACT","01083198962","jixm@ccmu.edu.cn",{"name":94,"role":90,"phone":11,"phoneExt":11,"email":11},"Chuanjie Wu, PhD\u002FMD",[96,108,117,125,133,141,149,157,165,173,184,195,203],{"facility":97,"status":98,"city":99,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":102,"geoPoint":107,"contacts":11},"Anyang People's Hospital","NOT_YET_RECRUITING","Anyang","China","CN",{"type":103,"coordinates":104},"Point",[105,106],114.38278,36.096,{"lat":106,"lon":105},{"facility":109,"status":110,"city":111,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":112,"geoPoint":116,"contacts":11},"Xuanwu Hospital，Capital Medical University","RECRUITING","Beijing",{"type":103,"coordinates":113},[114,115],116.39723,39.9075,{"lat":115,"lon":114},{"facility":118,"status":110,"city":119,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":120,"geoPoint":124,"contacts":11},"Anji County People's Hospital","Huzhou",{"type":103,"coordinates":121},[122,123],120.0933,30.8703,{"lat":123,"lon":122},{"facility":126,"status":110,"city":127,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":128,"geoPoint":132,"contacts":11},"Jiuquan People's Hospital","Jiuquan",{"type":103,"coordinates":129},[130,131],98.51736,39.74318,{"lat":131,"lon":130},{"facility":134,"status":110,"city":135,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":136,"geoPoint":140,"contacts":11},"Lishui Central Hospital","Lishui",{"type":103,"coordinates":137},[138,139],119.91029,28.46042,{"lat":139,"lon":138},{"facility":142,"status":110,"city":143,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":144,"geoPoint":148,"contacts":11},"Shangqiu First People's Hospitl","Shangqiu",{"type":103,"coordinates":145},[146,147],115.65613,34.4143,{"lat":147,"lon":146},{"facility":150,"status":110,"city":151,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":152,"geoPoint":156,"contacts":11},"Suzhou Municipal Hospital of Anhui Province","Suzhou",{"type":103,"coordinates":153},[154,155],120.59538,31.30408,{"lat":155,"lon":154},{"facility":158,"status":110,"city":159,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":160,"geoPoint":164,"contacts":11},"Taizhou Enze Medical Center (Group) Enze Hospital","Taizhou",{"type":103,"coordinates":161},[162,163],119.90812,32.49069,{"lat":163,"lon":162},{"facility":166,"status":110,"city":167,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":168,"geoPoint":172,"contacts":11},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou",{"type":103,"coordinates":169},[170,171],117.28386,34.20442,{"lat":171,"lon":170},{"facility":174,"status":110,"city":175,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Yueqing People's Hospital","Yueqing",{"type":103,"coordinates":177},[178,179],120.96121,28.11941,{"lat":179,"lon":178},[182],{"name":183,"role":90,"phone":11,"phoneExt":11,"email":11},"Saizhen Wu",{"facility":185,"status":110,"city":186,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Yulin Second People's Hospital","Yulin",{"type":103,"coordinates":188},[189,190],110.14686,22.6305,{"lat":190,"lon":189},[193],{"name":194,"role":90,"phone":11,"phoneExt":11,"email":11},"Sheng Yang",{"facility":196,"status":110,"city":197,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":198,"geoPoint":202,"contacts":11},"Zhangpu County Hospital","Zhangzhou",{"type":103,"coordinates":199},[200,201],117.65556,24.51333,{"lat":201,"lon":200},{"facility":204,"status":110,"city":205,"state":11,"zip":11,"country":100,"countryCode":101,"cosmosGeoPoint":206,"geoPoint":210,"contacts":11},"Zibo Central Hospital","Zibo",{"type":103,"coordinates":207},[208,209],118.06333,36.79056,{"lat":209,"lon":208},{"type":212,"investigatorFullName":213,"investigatorTitle":214,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ji Xunming,MD,PhD","Professor of Neurology, Xuanwu Hospital, Capital Medical University","100654490","phase-2-anisodine-hydrobromide-for-patients-with-acute-ischemic-stroke-undergoing-endovascular-therapy-heal-2-100654490",false,"NCT07800572","Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)","Efficacy and Safety of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment","Inclusion Criteria:\n\n* Age 18-80 years\n* Anterior-circulation large-vessel occlusion involving the intracranial ICA, M1, or proximal\u002Fdominant M2\n* Eligible for endovascular treatment within 24 hours of last known well\n* Baseline NIHSS score ≥6\n* Baseline ASPECTS ≥6\n* Pre-stroke mRS score 0-1\n* Written informed consent provided by the participant or legally authorized representative\n\nExclusion Criteria:\n\n* Intracranial hemorrhage on baseline imaging\n* Significant bleeding disorder or coagulopathy\n* Vascular anatomy unsuitable for EVT\n* Pregnancy, breastfeeding, or planned pregnancy within 90 days\n* Known hypersensitivity or severe intolerance to anisodine hydrobromide\n* Contraindication to anticholinergic drugs\n* Severe arrhythmia or hemodynamic instability\n* Severe psychiatric disorder, dementia, or impaired consciousness precluding consent or follow-up\n* Malignancy or other severe systemic disease with a life expectancy \\\u003C90 days\n* Participation in another clinical trial within 30 days before enrollment or concurrently\n* Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation","ALL","18 Years","80 Years",{"count":226,"type":227},204,"ESTIMATED","INTERVENTIONAL",[230],"PHASE2","This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.",[233],"Acute Ischemic Stroke",[235,236,237],"Endovascular Treatment","Neuroprotection","Stroke","2026-10-09",{"date":240,"type":241},"2026-10-13","ACTUAL",{"date":243,"type":241},"2026-09-06",{"date":245,"type":227},"2027-03-31",{"name":5,"class":6},13]